Akebia Therapeutics, Inc. (AKBA) Stock Forecast
Data as of Oct 31, 2026Healthcare · Current price $0.70 (-6.01%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Feb 6, 2026 | Allison Bratzel | Piper Sandler | $4.00 | +473.1% |
| Mar 28, 2024 | Ed Arce | H.C. Wainwright | $6.00 | +759.7% |
| Mar 3, 2022 | Serge Belanger | Needham | $7.00 | +903.0% |
Top Analysts Covering AKBA
AKBA vs Sector & Market
| Metric | AKBA | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.33 | 2.25 | 2.41 |
| Analyst Count | 3 | 8 | 19 |
| Target Upside | +43.3% | +153002.0% | +21.5% |
| P/E Ratio | -70.50 | 3.54 | 38.49 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $55M | $68M | $75M | 3 |
| 2027-03-31 | $25M | $31M | $34M | 3 |
| 2027-06-30 | $29M | $36M | $40M | 2 |
| 2027-09-30 | $32M | $40M | $44M | 2 |
| 2027-12-31 | $37M | $46M | $51M | 3 |
| 2028-12-31 | $202M | $252M | $297M | 4 |
| 2029-12-31 | $250M | $313M | $368M | 3 |
| 2030-12-31 | $339M | $424M | $499M | 3 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $0.02 | $0.02 | $0.02 | 1 |
| 2027-03-31 | $-0.11 | $-0.10 | $-0.07 | 1 |
| 2027-06-30 | $-0.10 | $-0.09 | $-0.06 | 1 |
| 2027-09-30 | $-0.08 | $-0.07 | $-0.06 | 1 |
| 2027-12-31 | $-0.07 | $-0.07 | $-0.05 | 1 |
| 2028-12-31 | $-0.01 | $0.07 | $0.25 | 4 |
| 2029-12-31 | $0.19 | $0.26 | $0.32 | 2 |
| 2030-12-31 | $0.47 | $0.64 | $0.78 | 2 |
Frequently Asked Questions
What is the analyst consensus for AKBA?
The consensus among 3 analysts covering Akebia Therapeutics, Inc. (AKBA) is Buy with an average price target of $1.00.
What is the highest price target for AKBA?
The highest price target for AKBA is $7.00, set by Serge Belanger at Needham on 2022-03-03.
What is the lowest price target for AKBA?
The lowest price target for AKBA is $4.00, set by Allison Bratzel at Piper Sandler on 2026-02-06.
How many analysts cover AKBA?
3 analysts have issued ratings for Akebia Therapeutics, Inc. in the past 12 months.
Is AKBA a buy or sell right now?
Based on 3 analyst ratings, AKBA has a consensus rating of Buy (2.33/5) with a +43.3% upside to the consensus target of $1.00.
What are the earnings estimates for AKBA?
Analysts estimate AKBA will report EPS of $0.02 for the period ending 2026-12-31, with revenue estimated at $68M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.